Widen­ing GLP-1 cov­er­age could cost Medicare al­most $150B an­nu­al­ly, study finds

8 months ago
Pharma

Eli Lil­ly re­leas­es sin­gle-dose vials of Zep­bound at half the price of oth­er obe­si­ty meds

8 months ago
Pharma
Manufacturing

As­traZeneca pours $135M in­to boost­ing bi­o­log­ics ca­pac­i­ty in Swe­den 

8 months ago
Pharma
Manufacturing

Du­al­i­ty Bi­o­log­ics, an ADC part­ner of BeiGene and BioN­Tech, files for Hong Kong IPO

8 months ago
Financing
Startups

Once-promis­ing can­cer drugs ap­pear to pro­tect mice from Alzheimer’s

8 months ago
R&D

Redalpine clos­es $200M fund; A base edit­ing pact in Chi­na; Mer­ck starts an­oth­er Phase 3 for Ima­go drug

8 months ago
News Briefing

For­mer Re­genxbio lead­ers take rare dis­ease gene ther­a­pies to start­up with $15M

8 months ago
Financing
Startups

In­vivyd says new Phase 3 da­ta on Covid an­ti­body sup­port pro­phy­lac­tic use

8 months ago
R&D
Coronavirus

Il­lu­mi­na wins FDA ap­proval for test to iden­ti­fy treat­able can­cers

8 months ago
FDA+
Diagnostics

Elek­trofi, a start­up that helps drug­mak­ers for­mu­late bi­o­log­ics for eas­i­er de­liv­ery, is rais­ing a $112M Se­ries C

8 months ago
Financing
Startups

RA Cap­i­tal and For­bion set up new au­toim­mune biotech with bis­pe­cif­ic from Ko­re­an start­up

8 months ago
Financing
Startups

Up­dat­ed: Oculis clos­es Phase 3 eye drop tri­al due to 'ad­min­is­tra­tive er­ror' from third par­ty

8 months ago
R&D

Pfiz­er un­veils di­rect-to-con­sumer push for Covid, flu and mi­graine treat­ments

8 months ago
Pharma
Coronavirus

Swiss biotech's in­hibitor of can­cer dri­ver shows promise in rare bleed­ing dis­or­der

8 months ago
R&D

Fed­er­al agency op­pos­es J&J's new 340B dis­count mod­el, promis­es to take 'ac­tions as war­rant­ed'

8 months ago
Pharma
FDA+

No­var­tis to sell mol­e­c­u­lar imag­ing busi­ness to Siemens Health­i­neers

8 months ago
Deals

An­oth­er ma­jor PBM will cut Ab­b­Vie's Hu­mi­ra from its largest com­mer­cial for­mu­la­ries

8 months ago
Pharma
Health Tech

Re­gen­eron wins EU ap­proval for lym­phoma bis­pe­cif­ic fol­low­ing FDA re­jec­tion

8 months ago
Pharma
FDA+

Once one of im­muno-on­col­o­gy's next great hopes, CD47 faces fi­nal shots on goal

8 months ago
R&D
In Focus

Mpox vac­cine col­lab; $11M on­col­o­gy seed; Gates backs RSV vac­cine; Ky­owa Kirin slims port­fo­lio

8 months ago
News Briefing

Ma­jor Gala­pa­gos in­vestor says it will push board on com­pa­ny's 'per­for­mance' and 's­trate­gic op­por­tu­ni­ties'

8 months ago
Financing
Pharma

Mubadala, CBC Group ink $680M deal for UCB’s neu­rol­o­gy and al­ler­gy port­fo­lio in Chi­na

8 months ago
Deals
China

Pep­tide biotech MBX sub­mits IPO plans, mak­ing a trio of post-La­bor Day Nas­daq hope­fuls

8 months ago
Financing
Startups

Tome plans lay­offs amid strug­gle; FDA turns away Re­gen­eron; Next-gen obe­si­ty start­up launch­es; James Sabry joins ...

8 months ago
Weekly
First page Previous page 104105106107108109110 Next page Last page
A service from the Financial Times